Gepatamin
Liver cytamin — Khavinson-school organ peptide fraction, oral tablet
Gepatamin (Liver cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A Khavinson-school polypeptide fraction from animal liver, 155mg per tablet. This one has a pharmacokinetic argument the rest of the shelf does not: whatever survives digestion enters the portal vein and reaches the liver first, at the highest concentration it will ever reach, before any of it sees the systemic circulation. For a liver-targeted product, first-pass hepatic extraction is the delivery mechanism rather than the loss.
Gepatamin quick facts
| Route | Oral |
| Frequency | Not established · Not established |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Oral |
| Evidence level | No published study of this product. The literature belongs to the parenteral extracts and the synthetic peptides of the same school. |
The best pharmacokinetic case in the cytamin line, and still no human data: a PubMed search for the product's name on 8 September 2026 returned zero records, and the only record containing the class word is a Russian nutrition review that lists cytamins among categories of bioactive substances for liver disease. A comprehensive metabolic panel with GGT before and after a pack would be the first liver measurement ever published on this product. Note the circular trap this category is known for: a raised enzyme is a reason to find out why, not a reason to buy something.
How Gepatamin works
A Khavinson-school polypeptide fraction from animal liver, 155mg per tablet. This one has a pharmacokinetic argument the rest of the shelf does not: whatever survives digestion enters the portal vein and reaches the liver first, at the highest concentration it will ever reach, before any of it sees the systemic circulation. For a liver-targeted product, first-pass hepatic extraction is the delivery mechanism rather than the loss.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Gepatamin
Buy Gepatamin at RUPharma →The evidence for Gepatamin
Graded by what exists behind each claim.
✅ Clinically validated
- None. PubTator3 search for the product name, 8 September 2026: zero records. The only record anywhere containing the class word *cytamins* is a Russian nutrition review that lists them among categories of bioactive substances for liver disease (Tokaev 2007) — a mention in a list, not a study.
📊 Correlative data
- The liver preparation has been in the explant series under two other names: Hepalin (Khavinson 2002) and calf-derived Ventvil at 0.01-100 ng/ml (Ryzhak 2015), plus a functional-morphology study of an organotypic liver culture (Riadnova 2002). No published statement says whether any of them is the material in this tablet.
🧪 Theoretical / extrapolated
- The one product on this shelf whose pharmacokinetics make sense. Whatever survives digestion enters the portal vein and reaches the liver first, at the highest concentration it will ever reach — first-pass extraction is the delivery mechanism rather than the loss. That inverts the usual oral-versus-injectable expectation, and nobody has tested it.
- It also inverts the risk. Supplement-associated liver injury is a recognized category and the products involved characteristically have undisclosed composition, which describes this tablet. A panel before starting is what stops a rising enzyme being blamed on the problem instead of on the new variable.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Gepatamin actually does
Every other page in this cohort has to argue around the gut. This one does not, and that makes it the most interesting product on the shelf. Whatever survives digestion and crosses the intestinal wall enters the portal vein and arrives at the liver first, at the highest concentration it will ever reach anywhere in the body, before a molecule of it has seen the systemic circulation. First-pass hepatic extraction is the reason most oral drugs lose potency; for a liver-targeted product it is the delivery mechanism. Gepatamin is the best pharmacokinetic case in the entire cytamin line, and it still has no human data.
The one PubMed record that contains the word ‘cytamins’ is about the liver, which is a coincidence worth reporting accurately. Tokaev 2007 is a Russian nutrition review of bioactive substances for liver disease, and it lists cytamins as one class alongside amino acids and their derivatives, vitamins, macro- and microelements and herbal actives. It is a review that names the category in a list. It reports no trial, no dose, no endpoint and no patients. A page that cited it as “published evidence for liver support” would be doing exactly the thing this site exists not to do.
The mechanism claim. Peptide fractions from liver are argued to act on gene expression and protein synthesis in hepatocytes Khavinson 2021 Khavinson 2001, and the liver is a tissue where that claim is at least plausible on its own terms: hepatocytes are professional protein synthesizers with high turnover and a demonstrated regenerative capacity, which is not true of most organs on this shelf.
The product. A 155 mg tablet of a nucleoprotein fraction from animal liver, 40 per pack, listed by a partner at $42. No published composition, no assay, no source species.
Cell, rodent, human — and where it stops
The name has two spellings, and the second one finds this product by name in a study of people. Gepatamin returns zero records. Hepatamin, the transliteration the Russian literature uses, returns two, and one is Emirova 2004, whose abstract states that the cytamins administered were hepatamin, epifamin and suprenamin. Run 9 September 2026. This page previously reported the zero, and the zero was an artifact of transliteration.
What that paper is, measured rather than summarized. A 2004 Russian pharmacology report that those three cytamins, in various combinations with ecdystene, apilak, vitamax and essentiale, increased the working ability of high-ranking athletes and potentiated the other agents. The abstract states no sample size, no randomization, no blinding, no placebo, no effect size and no endpoint definition, and every regimen it describes is a combination. So the honest grade is this: the liver tablet has been given to people and written up, by a group reporting a favorable result, in a form nobody can check. That is more than nothing and a long way short of a trial. Khavinson 2001 is a 2001 military-medicine note whose title states an aim and for which PubTator3 returns no abstract. Rozhkova 2007 is the same laboratory three years later, writing about carnosine. Ryzhak 2003 covers manufacturing and screening. Tokaev 2007 remains a nutrition review.
And for a liver product the missing measurement is glaring. The athletes paper scored work capacity. A liver preparation given to people has ALT, AST, GGT, bilirubin, albumin and INR available for a few dollars, and the one human study that names this tablet reported none of them.
The liver extract has been in the explant series from the start, under a different name each time, and that is worth noticing. Khavinson 2002 lists the liver preparation as Hepalin; Ryzhak 2015 lists the calf liver polypeptide as Ventvil, tested at 0.01 to 100 ng/ml on organotypic liver cultures from young and old rats. Same school, same organ, two product names, and no published statement anywhere that either is the material in this tablet.
The most detailed liver result in the school is a morphology study. Riadnova 2002 reports the functional morphology of an organotypic liver culture exposed to the peptide, which is a structural readout rather than a functional one — it describes what the tissue looked like, not what it did. Kuznik 2020 extends the line to a polypeptide liver complex and the tetrapeptide KEDA. Explants and cell cultures throughout.
Where it stops, and it is a shorter distance than on any other page here. The chain is cell culture, in rats, at nanogram concentrations, applied directly. The missing step is a human liver with a measured number attached. And because the liver has the densest panel of routine blood tests of any organ in the body — transaminases, GGT, bilirubin, albumin, INR, and fibrosis scores on top — that missing step is not missing for want of instruments.
Gepatamin pharmacokinetics — how much of it actually gets in
What degrades it, and the sequence has an extra stage here. Acid, pepsin, pancreatic protease and brush-border peptidase hydrolysis as usual — and then, uniquely for this organ, whatever crosses the enterocyte is delivered by the portal vein straight into the hepatic sinusoids. For most compounds first-pass hepatic metabolism is the loss. For a product whose target is the liver it is the destination.
The oral barrier, and the number that makes this page different. Portal blood flow is roughly 1 liter per minute and it carries about 75% of total hepatic blood supply. An absorbed dose therefore reaches hepatocytes at a concentration set by portal flow rather than by whole-body distribution volume — a much smaller denominator. Take a 155 mg tablet, allow a deliberately pessimistic 1% intact absorption over an hour: 1.55 mg into roughly 60 liters of portal blood in that hour is around 26 ng/ml arriving at the liver, which lands inside the 0.01-100 ng/ml band the explant work used Ryzhak 2015. Systemically the same absorption would give about 310 ng/ml peak but spread over the whole body. Either way the liver sees the explant concentration first.
That is the strongest quantitative argument any product in this cohort has, and it is still only an argument. Every term in it is an assumption: the 1% intact-absorption figure has never been measured for this or any cytamin, the tablet's peptide content is unpublished, and the explant band was established by bathing tissue continuously rather than by a transient portal spike. State the arithmetic, then state what it rests on. It rests on nothing that has been measured.
The route comparison. Parenteral liver peptide preparations exist in this family, and for this organ specifically an injection is the weaker route on paper: an injected dose reaches the liver only via systemic recirculation, at a fraction of a portal concentration. That inversion — oral being mechanistically preferable — is true of no other product on this shelf, and nobody has run the comparison that would test it.
What would have to be true, and how you would know it was not
Four predictions. The liver is the most measurable organ in medicine, so none of these is expensive.
1. A comprehensive metabolic panel with GGT, before and after. One tube, standard panel, plus gamma-glutamyl transferase, drawn before the first tablet and at 40 days. GGT is the most sensitive routine marker of hepatic enzyme induction and biliary irritation and it is the one most often left off a basic panel. Zero published studies of this product have drawn any liver test at all.
2. Against the product: nothing will move in a healthy liver. The explant literature reports effects that are larger in tissue from old animals Ryzhak 2015 Khavinson 2002, and a normal metabolic panel has very little room to improve. Prediction: unchanged. The population where a change is even conceivable is people with an abnormal baseline, which is also the population that should not be self-managing a liver abnormality.
3. An enhanced liver fibrosis score is the endpoint the class claim actually implies. The gene-expression and regeneration argument is about tissue structure over months, not enzymes over weeks. ELF is a blood test, it is validated against biopsy, and it would be the appropriate endpoint for a course-based product. It has never been reported for anything in this family.
4. The prediction that would be a safety finding rather than an efficacy one. If transaminases or GGT rise during a course, the tablet is the most likely new variable and the correct response is to stop and re-test rather than to attribute it to the liver problem the product was bought for. Supplement-associated liver injury is common enough to be a recognized category, and a product with no published composition is exactly the kind that features in it.
What nobody has tested yet
Nobody has tested the one product on this shelf whose pharmacokinetics make sense. Everything above says the liver is the favorable case for oral organ-extract dosing. That makes the absence of a single before-and-after liver panel the most conspicuous gap in the cohort. Ten people, two panels each, and this product would have more human data than any cytamin ever published.
Nobody has said whether Hepalin, Ventvil and this tablet are the same material. Three names for a liver peptide preparation appear across the school's own literature Khavinson 2002 Ryzhak 2015 and the commercial catalog. Tandem mass spectrometry on one lot of each, compared peptide by peptide, would establish whether the explant results transfer to the tablet at all. Zero compositional comparisons have been published between any two products in this catalog.
Nobody has looked in portal blood, and in this one case it is not an unreasonable ask. Patients undergoing hepatic procedures have portal access. A single post-dose portal sample analyzed for peptide content would convert the central argument of this page into a measurement, and it is the only organ on this shelf where such a sample is ever taken.
Extrapolation, labeled as such. If the portal-delivery argument is right, three consequences follow that nobody has tested: the oral form should outperform the injectable for this organ, which inverts the usual expectation; the effect should be blunted by anything that reduces splanchnic blood flow, such as heavy exercise shortly after dosing; and it should be larger when taken fasted, because a protein-rich meal floods the same absorption pathways with competing di- and tripeptides. All three are testable, all three are cheap, and none has been attempted.
Gepatamin — its own safety story, not its class's
Three things specific to swallowing a liver preparation.
The liver is the organ most likely to be injured by the thing taken to help it. Herbal and dietary supplement hepatotoxicity is a recognized cause of drug-induced liver injury, and the products involved are characteristically ones with undisclosed or variable composition — which describes this tablet exactly. The specific trap is circular: someone with a raised transaminase takes a liver product, the number rises further, and the rise is attributed to the original problem rather than to the new variable. A panel before starting is what breaks that circle, and it costs less than the pack.
A raised liver enzyme is a reason to find out why, not a reason to buy something. The differential includes fatty liver, alcohol, viral hepatitis, hemochromatosis, autoimmune hepatitis, thyroid disease and muscle injury, and several of those are treatable in ways that materially change outcome. Forty days of an unstudied tablet is forty days not spent on that list. This is the same argument the prostate page makes about symptoms, and it applies harder here because the workup is a blood test rather than an examination.
The zero, and the sourcing gap behind it. No adverse event has been published for this product and no study of it has been published; the only record naming the class is a nutrition review Tokaev 2007. Animal-tissue origin with no published source species, country or processing controls is a question the synthetic peptides in this catalog do not raise, and for a product taken by someone with existing liver disease it is not an academic one.
Sources read for this page
- Emirova LR, Rozhkova EA, Paniushkin VV, Mirzoian RS, Seifulla NR. [The effects of cytamines and their combinations with ecdystene, apilak, vitamax, and essentiale on the work capability of athletes]. Eksperimental'naia i Klinicheskaia Farmakologiia 2004 [Russian] · PMID 15341074
- Khavinson VKh, Cherniak SI, D'iakonov MM. [Cytamines--preparations for maintaining high professional ability and longevity in servicemen]. Voenno-Meditsinskii Zhurnal 2001 [Russian] · PMID 11338817
- Ryzhak GA, Nekrasov PA, Kiselev OI, Khavinson VKh. Study of protein components of natural peptide regulators. Bulletin of Experimental Biology and Medicine 2003 · PMID 12717513
- Rozhkova EA, Ordzhonikidze ZG, Druzhinin AE, Seifulla NR, Paniushkin VV, Kuznetsov IuM. [Using carnosine and natural antioxidants for the prophylaxis of acute post-loading oxidative stress]. Eksperimental'naia i Klinicheskaia Farmakologiia 2007 [Russian] · PMID 18074807
- Tokaev ES. [Bioactive substance used for treatment and preventive maintenance of liver diseases]. Voprosy Pitaniia 2007 [Russian] · PMID 17802767
- Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI. [Tissue-specific action of peptides in tissue culture of rats of various ages]. Advances in Gerontology 2002;9:95-100 [Russian] · PMID 12096446
- Riadnova IIu, Filippov SV, Iuzhakov VV. Functional morphology of an organotypic liver culture exposed to the peptide livagen. Advances in Gerontology 2002 [Russian] · PMID 12577697
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Kuznik BI. The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Advances in Gerontology 2020 [Russian] · PMID 32362099
- Khavinson VK. Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine 2001;132(2):807-808 · PMID 11713572
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
Gepatamin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Gepatamin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Gepatamin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Gepatamin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Gepatamin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Gepatamin — frequently asked questions
What is Gepatamin?
Gepatamin (Liver cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A Khavinson-school polypeptide fraction from animal liver, 155mg per tablet. This one has a pharmacokinetic argument the rest of the shelf does not: whatever survives digestion enters the portal vein and reaches the liver first, at the highest concentration it will ever reach, before any of it sees the systemic circulation. For a liver-targeted product, first-pass hepatic extraction is the delivery mechanism rather than the loss.
Where can I find Gepatamin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Gepatamin protocol are available to members inside Skool. This public page covers what Gepatamin is, how it works and the evidence.
What is the half-life of Gepatamin?
Gepatamin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Gepatamin?
Current evidence level: No published study of this product. The literature belongs to the parenteral extracts and the synthetic peptides of the same school.. Gepatamin is offered for research purposes only and is not an approved medicine.
What Gepatamin is used for
Gepatamin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.